1. van Meerbeeck JP, Fennell DA, De Ruysscher DK: Small-cell lung cancer. Lancet (London, England) 2011, 378(9804):1741-1755.
2. Gazdar AF, Minna JD: Developing New, Rational Therapies for Recalcitrant Small Cell Lung Cancer. Journal of the National Cancer Institute 2016, 108(10).
3. Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, Eberhardt WE, van Meerbeeck J, Rami-Porta R: The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016, 11(3):300-311.
4. Alvarado-Luna G, Morales-Espinosa D: Treatment for small cell lung cancer, where are we now?-a review. Translational lung cancer research 2016, 5(1):26-38.
5. Yu WD, Wang H, He QF, Xu Y, Wang XC: Long noncoding RNAs in cancer-immunity cycle. Journal of cellular physiology 2018, 233(9):6518-6523.
6. Kobayashi M, Ikezoe T, Uemura Y, Ueno H, Taguchi H: Long-term survival of a patient with small cell lung cancer associated with cancer-associated retinopathy. Lung cancer (Amsterdam, Netherlands) 2007, 57(3):399-403.
7. Maddison P, Gozzard P, Grainge MJ, Lang B: Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2017, 88(14):1334-1339.
8. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D et al: Effector memory T cells, early metastasis, and survival in colorectal cancer. The New England journal of medicine 2005, 353(25):2654-2666.
9. Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA et al: Inferring tumour purity and stromal and immune cell admixture from expression data. Nature communications 2013, 4:2612.
10. Muppa P, Parrilha Terra SBS, Sharma A, Mansfield AS, Aubry MC, Bhinge K, Asiedu MK, de Andrade M, Janaki N, Murphy SJ et al: Immune Cell Infiltration May Be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019, 14(7):1286-1295.
11. Yang S, Zhang Z, Wang Q: Emerging therapies for small cell lung cancer. Journal of hematology & oncology 2019, 12(1):47.
12. Reck M, Heigener D, Reinmuth N: Immunotherapy for small-cell lung cancer: emerging evidence. Future oncology (London, England) 2016, 12(7):931-943.
13. Lin C, Yang L: Long Noncoding RNA in Cancer: Wiring Signaling Circuitry. Trends in cell biology 2018, 28(4):287-301.
14. Mercer TR, Dinger ME, Mattick JS: Long non-coding RNAs: insights into functions. Nature reviews Genetics 2009, 10(3):155-159.
15. Lipovich L, Johnson R, Lin CY: MacroRNA underdogs in a microRNA world: evolutionary, regulatory, and biomedical significance of mammalian long non-protein-coding RNA. Biochimica et biophysica acta 2010, 1799(9):597-615.
16. Atianand MK, Caffrey DR, Fitzgerald KA: Immunobiology of Long Noncoding RNAs. Annual review of immunology 2017, 35:177-198.
17. Chen YG, Satpathy AT, Chang HY: Gene regulation in the immune system by long noncoding RNAs. Nature immunology 2017, 18(9):962-972.
18. Peng D, Wang L, Li H, Cai C, Tan Y, Xu B, Le H: An immune infiltration signature to predict the overall survival of patients with colon cancer. IUBMB life 2019, 71(11):1760-1770.
19. Zhang B, Wang Q, Fu C, Jiang C, Ma S: Exploration of the immune-related signature and immune infiltration analysis for breast ductal and lobular carcinoma. Annals of translational medicine 2019, 7(23):730.
20. Wei ZW, Wu J, Huang WB, Li J, Lu XF, Yuan YJ, Xiong WJ, Zhang XH, Wang W, He YL et al: Immune-infiltration based signature as a novel prognostic biomarker in gastrointestinal stromal tumour. EBioMedicine 2020, 57:102850.
21. Shen Y, Peng X, Shen C: Identification and validation of immune-related lncRNA prognostic signature for breast cancer. Genomics 2020, 112(3):2640-2646.
22. Wei C, Liang Q, Li X, Li H, Liu Y, Huang X, Chen X, Guo Y, Li J: Bioinformatics profiling utilized a nine immune-related long noncoding RNA signature as a prognostic target for pancreatic cancer. Journal of cellular biochemistry 2019, 120(9):14916-14927.
23. Hong W, Liang L, Gu Y, Qi Z, Qiu H, Yang X, Zeng W, Ma L, Xie J: Immune-Related lncRNA to Construct Novel Signature and Predict the Immune Landscape of Human Hepatocellular Carcinoma. Molecular therapy Nucleic acids 2020, 22:937-947.
24. Zhu X, Tian X, Yu C, Shen C, Yan T, Hong J, Wang Z, Fang JY, Chen H: A long non-coding RNA signature to improve prognosis prediction of gastric cancer. Molecular cancer 2016, 15(1):60.
25. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D et al: T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast cancer research : BCR 2009, 11(2):R15.
26. Ni L, Dong C: New B7 Family Checkpoints in Human Cancers. Molecular cancer therapeutics 2017, 16(7):1203-1211.
27. Ma Y, Li J, Wang H, Chiu Y, Kingsley CV, Fry D, Delaney SN, Wei SC, Zhang J, Maitra A et al: Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer. Gastroenterology 2020, 159(1):306-319.e312.
28. Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, Logtenberg MEW, Slagter M, Rozeman EA, Hofland I et al: Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 2017, 549(7670):106-110.
29. Dougall WC, Kurtulus S, Smyth MJ, Anderson AC: TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunological reviews 2017, 276(1):112-120.
30. Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W et al: Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer cell 2021, 39(3):346-360.e347.
31. Song Y, Sun Y, Sun T, Tang R: Comprehensive Bioinformatics Analysis Identifies Tumor Microenvironment and Immune-related Genes in Small Cell Lung Cancer. Combinatorial chemistry & high throughput screening 2020, 23(5):381-391.
32. Bi N, Cao J, Song Y, Shen J, Liu W, Fan J, He J, Shi Y, Zhang X, Lu N et al: A microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapy. PLoS One 2014, 9(3):e91388.
33. Huarte M: The emerging role of lncRNAs in cancer. Nature medicine 2015, 21(11):1253-1261.
34. Qi P, Du X: The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2013, 26(2):155-165.
35. Xu J, Meng Q, Li X, Yang H, Xu J, Gao N, Sun H, Wu S, Familiari G, Relucenti M et al: Long Noncoding RNA MIR17HG Promotes Colorectal Cancer Progression via miR-17-5p. Cancer research 2019, 79(19):4882-4895.
36. Zhou Y, Zhu Y, Xie Y, Ma X: The Role of Long Non-coding RNAs in Immunotherapy Resistance. Frontiers in oncology 2019, 9:1292.
37. Zhao H, Liu X, Yu L, Lin S, Zhang C, Xu H, Leng Z, Huang W, Lei J, Li T et al: Comprehensive landscape of epigenetic-dysregulated lncRNAs reveals a profound role of enhancers in carcinogenesis in BC subtypes. Molecular therapy Nucleic acids 2021, 23:667-681.
38. Zhao L, Ji G, Le X, Wang C, Xu L, Feng M, Zhang Y, Yang H, Xuan Y, Yang Y et al: Long Noncoding RNA LINC00092 Acts in Cancer-Associated Fibroblasts to Drive Glycolysis and Progression of Ovarian Cancer. Cancer research 2017, 77(6):1369-1382.
39. Huang W, Liu Z, Li Y, Liu L, Mai G: Identification of long noncoding RNAs biomarkers for diagnosis and prognosis in patients with colon adenocarcinoma. Journal of cellular biochemistry 2019, 120(3):4121-4131.
40. Wu J, Li M, Zhang Y: Long noncoding RNA HOXA-AS2 regulates the expression of SCN3A by sponging miR-106a in breast cancer. Journal of cellular biochemistry 2019, 120(9):14465-14475.
41. Wang X, Wang X, Huang G, Chen Y: Lower expression of LINC00092 in lung adenocarcinoma might mean poorer prognosis: A study based on data mining and bioinformatics. Medicine 2020, 99(44):e23012.
42. Gong Z, Li J, Cang P, Jiang H, Liang J, Hou Y: RPL34-AS1 functions as tumor suppressive lncRNA in esophageal cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2019, 120:109440.
43. Jiang Y, Du F, Chen F, Qin N, Jiang Z, Zhou J, Jiang T, Pu Z, Cheng Y, Chen J et al: Potentially functional variants in lncRNAs are associated with breast cancer risk in a Chinese population. Molecular carcinogenesis 2017, 56(9):2048-2057.
44. Cai HJ, Zhuang ZC, Wu Y, Zhang YY, Liu X, Zhuang JF, Yang YF, Gao Y, Chen B, Guan GX: Development and validation of a ferroptosis-related lncRNAs prognosis signature in colon cancer. Bosnian journal of basic medical sciences 2021.
45. Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg S et al: CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 2017, 549(7670):101-105.
46. Chauvin JM, Zarour HM: TIGIT in cancer immunotherapy. Journal for immunotherapy of cancer 2020, 8(2).